MA44209B1 - Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate - Google Patents

Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Info

Publication number
MA44209B1
MA44209B1 MA44209A MA44209A MA44209B1 MA 44209 B1 MA44209 B1 MA 44209B1 MA 44209 A MA44209 A MA 44209A MA 44209 A MA44209 A MA 44209A MA 44209 B1 MA44209 B1 MA 44209B1
Authority
MA
Morocco
Prior art keywords
phosphorodiamidate oligomer
phosphorodiamidate
oligomer
preparation
pharmaceutical composition
Prior art date
Application number
MA44209A
Other languages
English (en)
Other versions
MA44209A (fr
Inventor
Atsushi Endo
Robert T Yu
Francis Fang
Hyeong Wook Choi
Mingde Shan
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MA44209A publication Critical patent/MA44209A/fr
Publication of MA44209B1 publication Critical patent/MA44209B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nucléosides morpholino phosphoramidochloridate activés diastéréomériquement purs ou sensiblement diastéréomériquement purs, des procédés pour leur préparation, et des procédés pour leur utilisation en couplage stéréospécifique pour la synthèse stéréospécifique d'oligomères morpholino phosphorodiamidate (pmo) diastéréomériquement purs.
MA44209A 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate MA44209B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562201510P 2015-08-05 2015-08-05
PCT/US2016/045876 WO2017024264A2 (fr) 2015-08-05 2016-08-05 Réactifs chiraux pour la préparation d'oligomères homogènes

Publications (2)

Publication Number Publication Date
MA44209A MA44209A (fr) 2021-04-28
MA44209B1 true MA44209B1 (fr) 2022-03-31

Family

ID=56943909

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44209A MA44209B1 (fr) 2015-08-05 2016-08-05 Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate

Country Status (31)

Country Link
US (4) US10457698B2 (fr)
EP (2) EP3331891B1 (fr)
JP (4) JP6978406B2 (fr)
KR (2) KR20250005537A (fr)
CN (3) CN117924364A (fr)
AU (3) AU2016302009B2 (fr)
CA (2) CA2994842A1 (fr)
CL (1) CL2018000322A1 (fr)
CO (1) CO2018001615A2 (fr)
CY (1) CY1125552T1 (fr)
DK (1) DK3331891T3 (fr)
ES (2) ES2907629T3 (fr)
HR (1) HRP20220129T1 (fr)
HU (2) HUE067910T2 (fr)
IL (3) IL293066A (fr)
LT (1) LT3331891T (fr)
MA (1) MA44209B1 (fr)
MD (1) MD3331891T2 (fr)
MX (2) MX389022B (fr)
MY (1) MY196627A (fr)
NZ (2) NZ778825A (fr)
PE (2) PE20231843A1 (fr)
PH (1) PH12018500265A1 (fr)
PL (1) PL3331891T3 (fr)
PT (1) PT3331891T (fr)
RS (1) RS62930B1 (fr)
SI (1) SI3331891T1 (fr)
SM (1) SMT202200089T1 (fr)
UA (1) UA123995C2 (fr)
WO (1) WO2017024264A2 (fr)
ZA (3) ZA201801518B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016302009B2 (en) * 2015-08-05 2021-09-30 Eisai R&D Management Co., Ltd. Chiral reagents for preparation of homogeneous oligomers
AU2017330276B2 (en) * 2016-09-20 2022-01-20 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
CN114901823A (zh) 2019-12-26 2022-08-12 日本新药株式会社 诱导外显子50的跳读的反义核酸
IL295967A (en) 2020-02-28 2022-10-01 Nippon Shinyaku Co Ltd Antisense nucleic acids for splicing on exon 51
CN117120456A (zh) 2020-12-11 2023-11-24 卫材R&D管理有限公司 聚-吗啉代寡核苷酸缺口体
US20220195437A1 (en) 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
TW202309283A (zh) 2021-04-28 2023-03-01 日商衛材R&D企管股份有限公司 反義寡核苷酸及其用於治療神經變性障礙之用途
IL317987A (en) * 2022-07-07 2025-02-01 Eisai R&D Man Co Ltd Crystalline monomers for preparing antisense oligonucleotides and methods for their preparation and use
CN120435317A (zh) 2022-10-27 2025-08-05 卫材R&D管理有限公司 肽-反义寡核苷酸及其用于治疗神经退行性障碍的用途
JP2026506527A (ja) * 2023-02-01 2026-02-25 アルナイラム ファーマシューティカルズ， インコーポレイテッド ６員環含有オリゴマー

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en) * 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en) 1999-07-16 2001-10-23 Agilent Technologies Inc. Biopolymer arrays and their fabrication
US7135565B2 (en) * 2000-07-28 2006-11-14 Agilent Technologies, Inc. Synthesis of polynucleotides using combined oxidation/deprotection chemistry
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
RU2606627C2 (ru) * 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
US9914745B2 (en) 2009-08-14 2018-03-13 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
ES2607603T3 (es) * 2010-09-30 2017-04-03 Nippon Shinyaku Co., Ltd. Derivado de ácido morfolino nucleico
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
CA3092114A1 (fr) * 2011-05-05 2012-11-08 Sarepta Therapeutics, Inc. Conjugues peptides/oligonucleotides
CN107266498B (zh) 2011-10-07 2023-10-03 吉利德科学公司 制备抗病毒核苷酸类似物的方法
HK1201514A1 (en) 2011-11-18 2015-09-04 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
US10066228B2 (en) 2011-11-30 2018-09-04 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
UA123398C2 (uk) 2015-08-05 2021-03-31 Янссен Байотек, Інк. Виділене антагоністичне антитіло, яке специфічно зв'язує cd154, та фармацевтична композиція, яка його містить
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
AU2016302009B2 (en) * 2015-08-05 2021-09-30 Eisai R&D Management Co., Ltd. Chiral reagents for preparation of homogeneous oligomers
DE102015214943A1 (de) 2015-08-05 2017-02-09 Siemens Aktiengesellschaft Verfahren und Anlage für eine chemische Synthese

Also Published As

Publication number Publication date
NZ778825A (en) 2024-11-29
SMT202200089T1 (it) 2022-03-21
ES2993126T3 (en) 2024-12-23
MX389022B (es) 2025-03-20
WO2017024264A2 (fr) 2017-02-09
RS62930B1 (sr) 2022-03-31
KR20250005537A (ko) 2025-01-09
PL3331891T3 (pl) 2022-03-28
MA44209A (fr) 2021-04-28
JP7712975B2 (ja) 2025-07-24
JP2018525380A (ja) 2018-09-06
DK3331891T3 (da) 2022-02-28
SI3331891T1 (sl) 2022-04-29
CA3296518A1 (en) 2026-03-02
EP3331891B1 (fr) 2021-12-15
US20250171475A1 (en) 2025-05-29
MY196627A (en) 2023-04-23
US10457698B2 (en) 2019-10-29
PH12018500265A1 (en) 2018-08-13
RU2018107663A3 (fr) 2020-05-21
WO2017024264A3 (fr) 2017-03-30
PE20180687A1 (es) 2018-04-23
CN108350005A (zh) 2018-07-31
JP2025090640A (ja) 2025-06-17
HK1248708A1 (zh) 2018-10-19
IL257353B (en) 2022-10-01
EP3331891A2 (fr) 2018-06-13
IL257353B2 (en) 2023-02-01
IL284611A (en) 2021-08-31
EP4039690B1 (fr) 2024-07-17
NZ778828A (en) 2024-11-29
HRP20220129T1 (hr) 2022-04-15
CL2018000322A1 (es) 2018-05-18
NZ740490A (en) 2024-07-05
PT3331891T (pt) 2022-02-28
CN108350005B (zh) 2024-02-06
KR20180044303A (ko) 2018-05-02
BR122023025447A2 (pt) 2024-01-16
LT3331891T (lt) 2022-02-25
CN113461733A (zh) 2021-10-01
JP7254869B2 (ja) 2023-04-10
ES2907629T3 (es) 2022-04-25
US20210171555A1 (en) 2021-06-10
IL284611B1 (en) 2023-07-01
ZA201801518B (en) 2020-10-28
CA2994842A1 (fr) 2017-02-09
EP4039690A1 (fr) 2022-08-10
JP2022003067A (ja) 2022-01-11
JP2023085402A (ja) 2023-06-20
RU2018107663A (ru) 2019-09-05
AU2021290235B2 (en) 2023-06-08
AU2016302009A1 (en) 2018-03-29
ZA201905394B (en) 2022-07-27
IL293066A (en) 2022-07-01
MD3331891T2 (ro) 2022-04-30
CO2018001615A2 (es) 2018-07-19
PE20231843A1 (es) 2023-11-21
EP4039690C0 (fr) 2024-07-17
CN117924364A (zh) 2024-04-26
AU2021290235A1 (en) 2022-01-20
MX2022000124A (es) 2022-02-16
IL284611B2 (en) 2023-11-01
US10836784B2 (en) 2020-11-17
HUE067910T2 (hu) 2024-11-28
KR102788397B1 (ko) 2025-04-01
AU2016302009B2 (en) 2021-09-30
UA123995C2 (uk) 2021-07-07
US20200115405A1 (en) 2020-04-16
MX2018001557A (es) 2018-05-02
CY1125552T1 (el) 2024-02-16
IL257353A (en) 2018-04-30
WO2017024264A8 (fr) 2018-04-12
HUE057593T2 (hu) 2022-05-28
US20180222932A1 (en) 2018-08-09
BR112018002430A2 (pt) 2018-09-18
AU2023226763B2 (en) 2025-09-18
ZA202201010B (en) 2024-05-30
AU2023226763A1 (en) 2023-09-28
JP6978406B2 (ja) 2021-12-08

Similar Documents

Publication Publication Date Title
MA44209B1 (fr) Procede de preparation d'un oligomere phosphorodiamidate substantiellement diastereomeriquement pure, un oligomere phosphorodiamidate faite par un tel procede et une composition pharmaceutique comprenant un tel oligomere phosphorodiamidate
MX2024007103A (es) Metodos de purificacion por columna de vectores aav.
ZA201708667B (en) Tyrosine kinase inhibitors
EP4516301A3 (fr) Composés contenant du nitrile pour utilisation comme médicaments
PH12022550033A1 (en) Compounds useful to treat influenza virus infections
MX2022016422A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
JOP20220020B1 (ar) مثبطات kars تعتمد على akr1c3 ثلاثية الحلقة
MY205512A (en) Arginase inhibitors
MX392008B (es) Mutaciones de la enzima crispr que reducen los efectos fuera del blanco
MY200590A (en) Compounds useful as kinase inhibitors
PE20191614A1 (es) Anticuerpo humanizado para tratar o prevenir trastornos cognitivos, proceso para producirlo, y agente para tratar o prevenir trastornos cognitivos usandolo
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
MX386086B (es) Composicion de cannabis
MX2018002099A (es) Compuestos y métodos para la administración transmembranal de moléculas.
EP3995581A3 (fr) Composés d'oligonucléotides pour traiter la pré-éclampsie et d'autres troubles angiogéniques
WO2016100261A3 (fr) Procédé de traitement du cancer avec cgamp ou cgasmp
MX2018002665A (es) Combinacion que comprende oligonucleotidos inmunoestimulantes.
JOP20200041A1 (ar) تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
MX2022003365A (es) Anticuerpos de un solo dominio dirigidos contra lilrb2.
PH12017500944A1 (en) New 2` and/or 5` amino-acid ester phosphoramidate 3`-deoxy adenosine derivatives as anti-cancer compounds
PH12017500231A1 (en) 6-alkynyl-pyridine derivatives as smac mimetics
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
ZA202204730B (en) Oligonucleotides with nucleoside analogs
CL2020003306A1 (es) Composiciones bifuncionales para el tratamiento del cáncer.
BR112014015007A2 (pt) esterilizador a vapor